Gilead Sciences has extended its collaboration with Nurix Therapeutics, impacting investor sentiment.
Gilead Sciences Inc has extended its E3 ligase collaboration with Nurix Therapeutics, which may influence the investment outlook for both companies. This partnership is crucial for advancing Gilead's therapeutic strategies, especially in oncology and autoimmune disorders. In the last trading session, Gilead's stock closed at US$145.07, reflecting a 1.82% increase for the day and a year-to-date gain of 22.94%.
Advertisement
Gilead Sciences Inc
GILD.US
GILD.US
Gilead Sciences Inc
WealthAwesomeMarket cap
$182.09B
Div. yield
2.23%
Div. / share
$3.22
52W high
$154.51
52W low
$111.27
1W change
-0.27%
Beta
0.33
Analyst Price Targets
Based on 27 analysts covering GILD · as of Oct 9, 2026
Wall Street analysts forecast GILD stock price to rise 438.3% over the next 12 months.
Consensus
Buy4.30 / 5.00
Avg. Target
C$159.27
+438.3% Upside
Previously C$158.65 on Oct 5, 2026
Current Price
C$29.59
Last close
Analyst Breakdown (27 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on GILD's historical volatility
30-Day Vol
20.3%
Annualized
90-Day Vol
27.0%
Annualized
Trend (90d)
+48.8%
Annualized drift
90d Mean
C$175.11
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$155.90 | C$145.34 – C$167.23 |
| 60 trading days | C$165.23 | C$149.62 – C$182.46 |
| 90 trading days | C$175.11 | C$155.07 – C$197.73 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should keep an eye on how this collaboration affects Gilead's future performance, especially given its current financial challenges.
Gilead's Stock Climbs 1.82% Following Collaboration News
In the latest trading session, Gilead's stock closed at US$145.07, with a trading volume of 1,275,186 shares. This volume is lower than its 20-day average of 5,799,951 shares, indicating reduced trading activity.
Bull case
The extension of this collaboration could lead to innovative treatments, potentially strengthening Gilead's position in the biotech sector.
Bear case
However, concerns persist about Gilead's current profit margins and overall financial health as it continues to invest in research and development.
Gilead Extends E3 Ligase Collaboration
Advertisement
Gilead Sciences has announced the extension of its collaboration with Nurix Therapeutics regarding E3 ligase technology. This partnership aims to enhance the development of targeted therapies, which could strengthen Gilead's portfolio in tackling complex diseases, particularly in oncology. The collaboration is expected to leverage Gilead's extensive resources and expertise in drug development, potentially leading to breakthroughs in treatment options. As investors evaluate this collaboration, they will be looking for updates on progress and any new therapies that arise from this partnership.
Market Response to Collaboration News
Following the announcement, Gilead's stock rose by 1.82%, closing at US$145.07. The trading volume was 1,275,186 shares, significantly lower than the 20-day average of 5,799,951 shares, indicating a decrease in trading activity. Gilead's stock has seen a minor decline of 1.48% over the past week and a 2.20% drop over the past month. Currently, the stock is positioned at 78% of its 52-week range, which spans from US$111.27 to US$154.51. Analysts have a favorable outlook, with an average target price of US$158.65, suggesting a potential upside of 9.4% from the last close.
Future Considerations for Gilead Investors
Investors should monitor how this collaboration impacts Gilead's research and development outcomes. The company's current profit margin stands at -10.6%, and its return on equity is -20.7%, raising concerns about its financial health as it invests heavily in innovation. Gilead's earnings per share (EPS) for the trailing twelve months is reported at -2.65. Additionally, the stock is trading above its 50-day moving average of US$143.78 and its 200-day moving average of US$136.94, indicating a potentially positive trend in market sentiment despite ongoing financial challenges.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
